Treatment of ursodeoxycholic acid with glucocorticoids and immunosuppressants may improve the long-term survival rate in primary biliary cholangitis patients
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000031395
Abstract: Primary biliary cholangitis (PBC) is an autoimmune cholestatic liver disease. The clinical effectiveness of ursodeoxycholic acid (UDCA) plus glucocorticoids and/or immunosuppressants remains controversial in PBC patients. The study aimed to compare the efficacy of monotherapy… read more here.
Keywords: long term; glucocorticoids immunosuppressants; therapy; term survival ... See more keywords
The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.928390
Abstract: The emergence of checkpoint inhibitors has created a paradigm shift for the treatment of various malignancies. However, although these therapies are associated with improved survival rates, they also carry the risk of immune-related adverse events… read more here.
Keywords: glucocorticoids immunosuppressants; checkpoint inhibitor; effects glucocorticoids; therapy ... See more keywords